Search results
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters· 2 hours agoAbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and< ...
Sanofi reports 1Q revenue increase, as sales of vaccines, Dupixent rise
WFMZ Eastern Pennsylvania and Western New Jersey· 7 hours agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in...
RSV vaccine boosts Monroe County's Sanofi Pasteur
WFMZ Eastern Pennsylvania and Western New Jersey· 7 hours agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in first-quarter revenue on Thursday, as sales of vaccines
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday ...
Zacks via Yahoo Finance· 5 hours ago(You can read the full research report on Danaher here >>>) Shares of Regeneron Pharmaceuticals have...
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily· 3 hours agoSanofi Stock: Dupixent Missed, But Solid In...41 billion. Dupixent, the Regeneron Pharmaceuticals...
Sanofi Sales, Profit Beat Expectations
Morningstar· 12 hours agoBy Helena Smolak Sanofi backed its full-year guidance after first-quarter sales and profit beat analysts expectations. The French pharmaceutical
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Seeking Alpha· 5 hours agoRegeneron Pharmaceuticals and Mammoth Biosciences join forces to develop CRISPR-based gene editing...
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Zacks via Yahoo Finance· 22 hours agoToday's Research Daily features new research reports on 16 major stocks, including Danaher...
Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy By Investing.com
Investing.com· 8 hours agoSanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
Q2 2024 EPS Estimates for Sanofi (NASDAQ:SNY) Cut by Leerink Partnrs
ETF DAILY NEWS· 5 days agoLeerink Partnrs analyst D. Risinger now expects that the company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.93. The consensus ...
